Annual report pursuant to Section 13 and 15(d)

Description of Business and Summary of Significant Accounting Policies - Additional Information (Detail)

v3.10.0.1
Description of Business and Summary of Significant Accounting Policies - Additional Information (Detail)
1 Months Ended 12 Months Ended
Jun. 01, 2017
USD ($)
Feb. 01, 2012
USD ($)
Oct. 10, 2001
USD ($)
shares
Dec. 31, 2005
USD ($)
Nov. 30, 2018
USD ($)
CompensationPlan
Agreement
Deliverables
Segments
Unit
shares
Nov. 30, 2017
USD ($)
shares
Nov. 30, 2016
USD ($)
Debt Securities, Available-for-sale [Line Items]              
Concentration risk related to supplier         Company depends on one supplier for the source of its collection kits    
Number of deliverables for revenue recognized | Deliverables         2    
Period of doubtful for accounts receivable due from client         21 years    
Contracted storage periods option two         21 years    
Contracted storage periods option one         1 year    
Contracted storage periods option three         Lifetime    
Deferred revenue recognition period         12 months    
Number of licensing agreement made by entity | Agreement         12    
Number of license agreement | Agreement         2    
Impairment on long lived assets         $ 0 $ 0  
Goodwill         $ 1,941,411 $ 0  
Minimum percentage probability of realized tax benefit on settlement         50.00% 50.00%  
Provisions for interest or penalties related to uncertain tax positions         $ 0 $ 0 $ 0
Uncertain tax provisions         0 0 $ 0
Advertising cost included in selling, general and administrative expenses         986,664 1,008,000  
Unrealized holding losses, trading securities         (28,000) (82,000)  
Unrealized (loss) gain on marketable securities, net of tax         300,119 6,457  
Payment warranty       $ 50,000      
Increased payment warranty $ 100,000 $ 75,000          
Additional payment warranty   $ 10,000          
Reserves recorded under programs         $ 18,000 18,000  
Number of employee stock based compensation plan | CompensationPlan         2    
Stock-based option compensation expense         $ 478,000 $ 972,000  
Stock compensation expense reversed         $ 444,000    
Stock compensation, number of shares opted to lump sum cash payment | shares         30,000    
Employee Stock Incentive Plan [Member]              
Debt Securities, Available-for-sale [Line Items]              
Number of outstanding options excluded from computation of diluted earnings per share | shares           22,500  
Saneron [Member]              
Debt Securities, Available-for-sale [Line Items]              
Ownership interest         33.00% 33.00%  
Saneron [Member] | CCEL Bio-Therapies, Inc. [Member]              
Debt Securities, Available-for-sale [Line Items]              
Non-Controlling interest after merger     43.42%        
Duke University [Member]              
Debt Securities, Available-for-sale [Line Items]              
Asset purchase agrrement closing date         Jan. 31, 2020    
Saneron Therapeutics, Inc. [Member] | CCEL Bio-Therapies, Inc. [Member]              
Debt Securities, Available-for-sale [Line Items]              
Issue of shares by parent and another subsidiary of parent to the share holder of company merged with wholly owned subsidiary | shares     260,000        
Fair value of shares issued by parent and another subsidiary of parent to the share holder of company merged with wholly owned subsidiary     $ 1,924,000        
Saneron Therapeutics, Inc. [Member] | Stem Cell Preservation Technologies, Inc. [Member]              
Debt Securities, Available-for-sale [Line Items]              
Issue of shares by parent and another subsidiary of parent to the share holder of company merged with wholly owned subsidiary | shares     195,000        
Fair value of shares issued by parent and another subsidiary of parent to the share holder of company merged with wholly owned subsidiary     $ 3,900        
Accounts Receivable [Member]              
Debt Securities, Available-for-sale [Line Items]              
Period of doubtful for accounts receivable due from client         30 days    
Umbilical Cord Blood and Cord Tissue Stem Cell Service and PrepaCyte-CB [Member]              
Debt Securities, Available-for-sale [Line Items]              
Number of reportable segments | Segments         3    
Umbilical Cord Blood and Cord Tissue Stem Cell Service and PrepaCyte-CB [Member] | Duke University [Member]              
Debt Securities, Available-for-sale [Line Items]              
Inventory, in units | Unit         6,000    
Number of units, per month | Unit         12    
Umbilical Cord Blood and Cord Tissue Stem Cell Service and PrepaCyte-CB [Member] | Duke University [Member] | Maximum [Member]              
Debt Securities, Available-for-sale [Line Items]              
Inventory, in units | Unit         144